Diagnosis and Management of Seizures in the Preterm Infant

Jaime-Dawn E Twanow1

  • 1Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, United States; The Ohio State University College of Medicine, Columbus, OH, United States.

Insights

Premature neonates have increased seizure risk and poorer neurodevelopmental outcomes. More research is crucial to guide effective seizure management in preterm infants.

Area of Science:

  • Neonatal neurology
  • Perinatal medicine
  • Developmental neuroscience

Background:

  • Seizures are more common in premature neonates than full-term infants.
  • Preterm infants with seizures face worse neurodevelopmental outcomes.
  • Current seizure management in preterm infants relies heavily on data from full-term infants.

Purpose of the Study:

  • To highlight the distinct seizure characteristics in premature neonates.
  • To emphasize the need for evidence-based guidelines for seizure management in this population.
  • To underscore the neurodevelopmental risks associated with seizures in preterm infants.

Main Methods:

  • Review of existing literature on neonatal seizures.
  • Analysis of seizure profiles (etiology, timing, character) in premature versus full-term infants.
  • Comparison of neurodevelopmental outcomes in different infant groups.

Main Results:

  • Premature neonates exhibit a unique seizure profile.
  • Seizures in preterm infants are linked to significantly higher risks of abnormal neurodevelopmental outcomes.
  • Existing treatment protocols are largely extrapolated from full-term infant data.

Conclusions:

  • There is a critical need for dedicated clinical trials for preterm neonates with seizures.
  • Validated, safe, and effective seizure management strategies are required for this vulnerable group.
  • Improved understanding and treatment are essential to mitigate long-term neurodevelopmental deficits.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
269
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
574
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
833
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
426
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
591
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
590